and exchangers, that are situated in the plasma membrane (PM) or in intracellular organelles such as the endoplasmic reticulum (ER) and mitochondria. [3] [4] [5] Interruptions in Ca 21 homeostasis may result in human diseases such as cardiovascular disease, immunodeficiency, diabetes and cancer. 6, 7 Invasive cancer is the leading cause of death. 8 Accumulating evidence suggests that Ca 21 -related signaling pathways represent promising new therapeutic targets for cancer. 2 Compared with nonmalignant cells, cancer cells undergo constant remodeling of Ca 21 signaling, with remarkable alterations in the expression and/or activity of calcium channels and pumps, 9 as well as in intracellular Ca 21 -dependent signaling components. Cancer cells do this to sustain their own proliferation and to avoid cell death response. 10 An understanding of the remodeling of Ca 21 signaling and of channel proteins in cancer is certainly anticipated to provide novel opportunities for therapeutic intervention. Store-operated calcium channels (SOCCs) are some of the most abundantly expressed channels in nonexcitable cells in which the emptying of intracellular Ca 21 stores activates Ca 21 influx through the PM. 11, 12 In this review, we primarily focus on the role of store-operated Ca 21 entry (SOCE) in cancer.
Overview of SOCE
Back in 1980 sec, Putney proposed that the depletion of Ca 21 store directly results in the activation of Ca 21 channels in the PM, a process now referred to as SOCE. 13 SOCE can be activated by ligand-induced activation of membrane receptors or by pharmacological manipulations that empty the intracellular Ca 21 stores that are located primarily in the ER. The most well-studied example of store-operated channel (SOC) is the calcium release-activated calcium (CRAC) channel that was initially characterized in human T cells and mast cells. 14, 15 Under physiological conditions, stimulation of diverse PM receptors such as G-protein-coupled receptors (GPCR) activates phospholipase C (PLC), which hydrolyzes phosphatidylinositol-4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol trisphosphate (IP3). IP3 binds to the Ca 21 -permeable IP3 receptor (IP3R) on the ER membrane and evokes Ca 21 release from the stores into the cytosol. 16 Once the stromal interaction molecule (STIM) protein senses a drop in ER Ca 21 levels, it undergoes conformational changes with subsequent migration toward the PM to open ORAI channels through direct physical coupling. 12, [17] [18] [19] [20] Functional interactions between the IP3 receptors and transient receptor potential (TRP) channels have also been reported to play modulatory roles during SOCE in certain types of cells. 21, 22 Implications of STIM-ORAI in SOCE During the last decade, the two major protein families STIM and ORAI 12, [17] [18] [19] were identified. STIM proteins (STIM1 and STIM2) are type I single-pass transmembrane proteins that are located predominantly in the ER. 23 As shown in Figure  1a , the domain structure of STIM1 includes the following: an N-terminal signal peptide, a canonical EF hand Ca 21 -binding motif, a hidden non-Ca 21 -binding EF hand and a sterile amotif (SAM) domain in the ER luminal region, a putative coiled-coil domain (CCD), a STIM-ORAI activating region (SOAR) or CRAC activation domain (CAD), a serine-or proline-rich clusters and a polybasic C-tail in the cytoplasmic region. 24 The EF-hand domain is responsible for sensing the Ca 21 fluctuation in the ER lumen, whereas the cytoplasmic domain, in particular the SOAR/CAD domain, 25, 26 directly gates and opens the ORAI channels. At rest, STIM1 is evenly distributed throughout the ER membrane. On depletion of Ca 21 stores, STIM1 undergoes rapid dimerization/oligomerization and moves into regions at the ER-PM junctions (termed puncta) so that they can physically interact with ORAI channels and elicits Ca 21 influx within a few seconds. 27 The STIM1 homologue STIM2 acts as a weaker activator of ORAI channels and is responsible for the maintenance of stable cytosolic and ER Ca 21 concentrations to prevent uncontrolled activation of SOCE. 28, 29 ORAI1 is a four-pass transmembrane protein whose Nand C-termini face the cytoplasm and is postulated to assemble as a tetramer or hexamer in the PM (Fig. 1b) . [30] [31] [32] The first transmembrane segment of ORAI1 forms the ionconducting pathway, which mediates Ca 21 influx. [32] [33] [34] The intracellular C-terminus of ORAI1 has been shown to form a coiled-coil structure, which interacts with the SOAR/CAD domain of STIM1. 19, 26, 30, [35] [36] [37] Disruption of coiled-coil formations in the C-tail of ORAI1 impairs STIM1-mediated activation of ORAI channels. 35 The N-terminus of ORAI1 is also essential for STIM1-mediated gating. It contains a calmodulin (CaM)-binding domain, which is involved in fast Ca 21 -dependent inactivation of ORAI channels. 38 In mammals, ORAI1 has two other homologues (ORAI2 and 3) that The ORAI1 protein contains four membrane-spanning regions and intracellular N-and C-termini. It also has a unique R/P-rich region in the N-terminus and a putative coiled-coil domain in its intracellular C-terminus. (c) The stimulation of PM receptors activates PLC, which leads to the production of the second messenger IP3. IP3 binds to the IP3R and elicits rapid Ca 21 release from the ER lumen. STIM1 senses Ca 21 decrease in ER and undergoes conformational changes to mediate ORAI gating, which results in Ca 21 influx through ORAI channels. The Ca 21 increase activates NFAT and a number of other transcription factors such as NF-jB and CREB, among others, which play crucial roles in cancer cells, endothelial cells, cells of the immune system and other nonhematopoietic cells.
can also be gated by STIM1 following store depletion. However, the ORAI1 protein has the highest potency in the conduction of Ca 21 currents, and thus the genetic depletion of ORAI1 substantially impairs SOCE. 39 Sustained elevation of intracellular Ca 21 through CRAC channels leads to the activation of the ubiquitous Ca 21 sensor CaM, which further activates the Ca 21 /CaM-dependent phosphatase calcineurin. 40 Calcineurin dephosphorylates multiple phosphoserines in the regulatory domain of the nuclear factor of activated T cells (NFAT), which leads to the nuclear translocation of NFAT within minutes (Fig. 1c) . In the nucleus, NFAT can cooperate with multiple transcription factors such as the activator protein 1 (AP1), forkhead box P-family protein (FOXP) and GATA to initiate the expression of multiple genes. These genes can then regulate diverse cellular functions, 40 including cell survival, proliferation, migration, invasion and angiogenesis. SOCE could also activate a number of other transcription factors such as cAMP-responsive elementbinding protein (CREB) and nuclear factor-jB (NF-jB) via the activation of calmodulin-dependent protein kinase II/IV (CaMKII/IV) and IjB kinase (IKK), respectively. [41] [42] [43] It has been shown that SOCE-mediated CREB activation promotes the proliferation of vascular smooth muscle cells (VSMCs). 44 NF-jB, which is stimulated by SOCE, is well known for its function in innate immunity, inflammation and oncogenesis. 45, 46 In turn, NF-jB stimulates the transcription of ORAI1 and STIM1, which play important roles in the regulation of platelet secretion, aggregation and thrombus formation. 47 
Implications of TRP Channels in SOCE
The TRP proteins are nonselective cation channels that were first identified in the trp mutant of Drosophila. 48 To date, approximately 30 different mammalian TRP channels have been identified according to their sequence homology. The TRP proteins have a common structure, including six transmembrane-spanning domains (S1-S6) with a loop region between the S5 and S6 domains and intracellular N-and Ctermini. 49 The role of Drosophila TRP proteins in SOCE was controversial as they were later found to behave as nonSOCs. 50 However, as the identification of TRP homologues in mammals, a body of evidence has supported a role for TRP channels in the conduction of SOCE, especially the transient receptor potential canonical (TRPC) subfamily members; these can be activated in response to stimuli, which results in PIP2 hydrolysis. 51 For example, the inhibition of transcription of native TRPC1 and TRPC3 channels in HEK cells could reduce Ca 21 influx after the depletion of Ca 21 stores. 52 The knockdown of other TRPC channels such as TRPC4 can inhibit SOCE in human corneal epithelial cells. 53 Together, these findings provide evidence to support a possible implication of TRP channels in SOCE in certain types of cells. [53] [54] [55] Interaction Between STIM1, ORAI and TRPC Proteins STIM1 can interact with all three ORAI proteins to induce SOCE. 56 Following the depletion of Ca 21 stores, the EF-SAM domains of STIM1 undergo oligomerization and initiate the translocation of STIM1 into the ER-PM junctions, which activates ORAI channels. 27 As a precise feedback mechanism, an elevation in the intracellular Ca 21 concentration leads to rapid Ca 21 -dependent inactivation (CDI) of the ORAI channel or dissociation of the STIM1-ORAI complex, which protects cells from ER Ca 21 overload. 57 The activation of ORAI channels is strictly dependent on STIM1, while the involvement of STIM1 in TRPC activation remains controversial. 58 It was reported that STIM1 could activate TRPC1, 2 and 4, where the ezrin/radixin/moesin (ERM) domain and the cationic lysine-rich region of STIM1 are required for the binding and gating of TRPC channels, respectively.
59 STIM1 does not interact with TRPC3 directly as it mediates the heteromultimerization of TRPC1 with TRPC3. 60 DeHaven et al. also reported that TRPC3 functions as a STIM1-dependent channel in the presence of TRPC1. 61 Overall, current evidence suggests that the depletion of Ca 21 stores results in a dynamic interplay between STIM1, ORAI and the TRPC proteins, where STIM1 communicates information from the ER lumen to the Ca 21 channels at the PM. 62 ORAI channels may mediate Ca 21 influx either independently or together with the TRPC proteins. 63, 64 The coordination of the STIM1, ORAI and TRPC proteins in mediating SOCE, as well as their possible regulatory mechanisms, is still a topic of debate and warrants further investigation.
Role of SOCE in Cancer
SOCE mediated by the STIM and ORAI proteins has recently been implicated in various processes during oncogenic transformation such as malignant transformation, apoptosis, proliferation, angiogenesis, metastasis and antitumor immunity. At the tumor initiation stage, Ca 21 signaling mediated by SOCE is needed to induce genetic changes in premalignant cells. These genetic alterations ultimately reprogram cells and cause them to undergo malignant transformation. 65 At the tumor development stage, blood vessels are necessary for tumor nutritional support. In cancer cells, SOCE promotes the secretion of vascular endothelial growth factor (VEGF), 66 which activates SOCE in endothelial cells by binding to its receptor; this subsequently promotes the proliferation of endothelial cells. 67 Interestingly, calcium signaling mediated by SOCE also plays a critical role in the antitumor activity of cytotoxic T lymphocytes (CTLs). 68 The following sections summarize recent advances in our understanding of SOCE in tumor cells as well as in other cell types within the tumor environment.
SOCE Regulates Apoptotic Cell Death, Proliferation and Metastasis of Cancer Cells
Sabbioni et al. reported that mRNA expression of STIM1 was absent in human rhabdomyosarcoma and rhabdoid tumor cell lines, and the forced expression of STIM1 caused growth arrest in these cells. 69 78 In addition, the blockage of STIM1-mediated SOCE can significantly enhance chemotherapyinduced apoptosis in lung and pancreatic cancer cells. 77, 84 Recent studies also indicate that ORAI3-mediated SOCE is involved in the tumorigenesis of estrogen receptor-positive breast cancer and non-small cell lung cancer. 85, 86 The molecular mechanisms of SOCE in the regulation of cancer cell proliferation and migration can be summarized as follows: (i) Inhibition of SOCE through STIM1 knockdown results in the upregulation of p21 and the downregulation of Cdc25C, cyclin E, cyclin D, CDCK2 and CDCK4, which eventually elicits cell cycle arrest. 66, 82 (ii) SOCE blockade through STIM1 or ORAI1 knockdown impairs focal adhesion turnover and cell migration. 66, 76, 79 Aberrant SOCE causes the activation of the Ca 21 -regulated protease calpain and the cytoplasmic kinase Pyk2, which regulate the focal adhesion dynamics of migratory cervical cancer cells. 66 The small GTPases Ras and Rac are also regulators of focal adhesion turnover. The expression of constitutively active Ras and Rac could rescue the defects of focal adhesion turnover and migration induced by the inhibition of SOCE in breast cancer cells. 79 (iii) Enhanced SOCE through STIM1 overexpression promotes the migration of colorectal cancer cells via an increase in the expression of cyclooxygenase-2 (COX-2) and the production of prostaglandin E2 (PGE2). 74 Ca 21 -dependent transcription factor NFAT may play an important role in this process. 87 NFAT also induces the transcription of many other proinvasive genes such as autotoxin. 88 As described above, STIM/ORAI-mediated SOCE plays important roles in the proliferation and metastasis of cancer cells. The exact function and mechanism are complicated and contextdependent, as summarized in Table 1 below. T cells is required to retard tumor growth in xenograft models of melanoma and colon carcinoma. This is because STIM1 and STIM2 deficiency in CD8 1 T cells significantly impairs their production of IFN-g and TNF-a, their expression of Fas ligand and degranulation of CTLs. 68 SOCE was also shown to participate in the cellular immune response as the blockage of SOCE by BTP2 significantly inhibited the antihost CTL response, donor T-cell expansion and IFN-g production in mouse models of graft-versus-host disease (GvHD). 111 Fuchs et al. reported that a homozygous R429C point mutation in STIM1 in two patients completely abolished SOCE in their T cells. This loss-of-function mutation of STIM1 resulted in a lack of NKT cells and in abnormal functions of NK-and FOXP3-positive regulatory T (Treg) cells, and eventually impaired antiviral immunity, which helps prevent chronic CMV and EBV infections. 112 Shaw et al. reported that STIM1/STIM2-mediated SOCE contributed to the differentiation and function of effector CD8 1 T cells during early acute virus infection. 113 More importantly, SOCE was found to regulate CD40L expression in CD4 1 T cells, which is essential for the maintenance of memory CD8 1 T cells and their ability to mediate recall responses and protection against secondary viral infections. 113 Recurrent and chronic viral infections such as EBV, CMV and human herpes virus 8 (HHV-8) result in the development of virus-associated tumors in SOCE-deficient patients. 113 For example, it was shown that T-cell immunodeficiency caused by STIM1 mutation accelerated the development of lethal Kaposi sarcoma (KS) upon infection with HHV-8. 114 ORAI-and STIM-mediated SOCE is also required for the cell differentiation and functions of traditional effector CD4 1 T cells, including Th1 and Th2 cells. 109 Notably, the proliferation of Th17 cells also appears to require SOCE. 115 
SOCE Regulates Tumor Angiogenesis

SOCEdeficient CD4
1 T cells grown under Th17 polarizing conditions in vitro failed to produce IL-17, which acts as a proinflammatory molecule to induce angiogenesis during tumor progression. 115 The production of IFN-g and IL-2 by Th1 cells is also decreased in the absence of SOCE. 116 However, IFN-g and IL-2 are commonly regarded as tumor inhibitory cytokines. 117, 118 Thus, the exact role of CD4 1 T-helper cells in tumor development is determined by its differentiation status. Interestingly, effector CD41 T cells appear to require varying degrees of SOCE for their maximal activity and exhibit differential sensitivity toward SOC inhibitors. For instance, the levels of SOCE required for the differentiation Because the function of the immune system during cancer progression is paradoxical, 124 it is necessary to be aware that not all of the immune responses that are regulated by SOCE are cancer protective. Thus, a clarification of the mechanisms and functions of SOCE in different types of immune cells in different stages of tumor development is important for a deeper understanding of the role of SOCE in antitumor immunity. In the early stages of tumorigenesis, SOCE is important for the normal function of immune surveillance system, which can prevent tumorigenesis. Once pathogens or cells escape immune surveillance, more immune cells are recruited and an inflammatory microenvironment is formed. It has been shown that chronic inflammation is the cause of various human cancers. 125 For example, patients with inflammatory bowel disease (IBD) have an increased risk for colorectal cancer. 126 Sustained Ca 21 flux via SOCE is necessary for the activation of immune cells in cases of chronic inflammation. Therefore, it is possible to avoid the initiation of tumor formation by inhibiting SOCE-involved chronic inflammation. However, as mentioned above, the functions of different types of immune cells are diverse, and their role in tumor immunity is sometimes different even for cells of the same cell type. For example, Th17 cells can promote tumor growth through IL-17 secretion, but it also prevents tumor development via the induction of the recruitment and activation of cytotoxic CD8 1 T cells within tumors. 127 Briefly, the role of SOCE in antitumor immunity is complicated and requires investigation in specific conditions. In particular, Weidinger et al. demonstrated that SOCE in CD8 1 T cells is critical for their cytotoxic activity against tumor cells. 68 The model used in this study was the engraftment of melanoma and colon carcinoma cells into conditional gene knockout mice, rather than a spontaneous tumor formation model. In summary, SOCE can directly regulate apoptotic cell death, proliferation and metastasis of cancer cells. SOCE also promotes VEGF secretion, which subsequently stimulates SOCE in vascular endothelial cells and leads to their proliferation for angiogenesis. Interestingly, in immune cells, SOCE plays a paradoxical role during cancer development. Figure 2 presents an overview of the primary signaling pathways that are regulated by SOCE in cancer cells and in cells of the tumor microenvironment. Because the function of immune cells in cancer is complicated, the xenograft model that was used in the latest work 68 could not fully mimic the tumor initiation and development process in vivo. Therefore, other well-designed experiments should be conducted before a final conclusion can be made with regard to the role of SOCE in modulating antitumor immunity.
Therapeutic Potential of SOCE in the Treatment of Cancer
As knowledge of SOCE in human disease accumulates, there has been an increased interest in the development of SOCE inhibitors that can be used to fight against cancer. Several small-molecule SOCE inhibitors have been developed over the past decades, which hold promise in the treatment of cancer.
SKF-96365
Primarily introduced as an inhibitor of receptor-operated calcium entry (ROCE), 130 the imidazole compound SKF-96365 was found to block SOCE in various cells such as mast, rat basophilic leukemia (RBL) and Jurkat cells. [131] [132] [133] SKF-96365 could block STIM1 overexpression-induced SOCE augmentation and NFAT nuclear translocation; this indicates that STIM1 is one of its potential targets. 59, 134 As an inhibitor of SOCE, SKF-96365 prevented tumor cell metastasis in a mouse model of breast cancer. 79 In another study, the blockade of SOCE by SKF-96365 retarded the growth and angiogenesis of cervical cancer cells. 66 However, SKF-96365 is not selective for CRAC channels and could block other Ca 21 channels, 131 and thus more studies need to be performed to specifically delineate its mechanisms in various types of cancer cells.
2-APB
Initial studies reported that 2-APB could inhibit IP3-induced Ca 21 release in rat cerebellar microsomes in a dose-dependent manner. 135 Later, it was found that its inhibitory effect was mainly due to a blockade of SOCE. 136 In addition, this inhibitory effect was IP3 receptor-independent and was more potent when it was applied extracellularly. 137 In native immune cells, 2-APB modulates SOCE activity in a paradoxical manner in that it exerts stimulatory effects at low concentrations and inhibitory effects at high concentrations. 137 This dual regulation is also observed in HEK293 cells. 138 It is speculated that low doses of 2-APB stimulate Ca 21 influx by promoting STIM1-ORAI1 interactions, while high doses inhibit SOCE in part due to its inhibition of STIM1 redistribution. 138 Interestingly, high doses of 2-APB could forcefully activate the ORAI3 channel and change its ion selectivity independently of STIM1 or Ca 21 store depletion. 56, 139 It has been postulated that 2-APB directly binds to the ORAI3 channel, which results in an increase in channel conductance and limits selectivity. 2-APB was reported to inhibit the proliferation of hepatoma, cervical and gastric cancer cells 66, 140, 141 and the migration of cervical and colorectal cancer cells.
74,89
Bistrifluoromethyl-pyrazole derivative, BTP2
First identified as a compound that blocks IL-2 production in lymphocytes, 142 BTP2 could potently and specifically inhibit SOCE in T lymphocytes without interference with other important Ca 21 influx pathways. 143 Additionally, BTP2 does not appear to affect STIM1 redistribution or STIM1-ORAI1 coupling. 144 Preincubation of Jurkat T-cells with BTP2 inhibits SOCE at an IC 50 of approximately 10 nM. 143 As mentioned above, the blockade of SOCE by BTP2 prevented antigen-induced T-cell responses through the inhibition of the antihost CTL response, donor T-cell expansion and IFNg production in mouse models of GvHD.
111 BTP2 could also inhibit antigen-induced cytokine secretion in mast cells, which is important in inflammation and antitumor immunity. 145 Mercer et al. showed that the actin reorganizing protein Drebrin was the target of BTP2 because the knockdown of Drebrin in Jurkat T cells inhibited SOCE similar to what occurred after treatment with BTP2. 146 
Anti-ORAI1 monoclonal antibodies
Because the ORAI1 protein is the pore subunit of the calcium channel responsible of SOCE and may serve as an attractive therapeutic target, specific anti-human ORAI1 monoclonal antibodies (mAbs) have been generated. 147 Recently, Cox et al. described a newly generated anti-ORAI1 mAb with specificity for the second extracellular loop that can inhibit T-cell activation in vitro and T-cell-mediated GvHD in vivo. This indicates its therapeutic potential for the treatment of autoimmune diseases and prevention of xenograft rejection. 148 
Other small molecular inhibitors
In recent years, several other small molecules have been developed as specific inhibitors of SOCE. 120, 149, 150 For Figure 2 . Proposed roles of SOCE in cancer. In tumor cells, SOCE promotes cancer cell proliferation via the upregulation of Cdc25C and the downregulation of p21. It also promotes cancer cell metastasis via the modulation of calpain-and Pyk2-mediated focal adhesion turnover or through upregulating the expression of COX-2, PGE2 and autotoxin. SOCE also contributes to drug resistance through an enhancement of AKT activity. In cancer cells, SOCE boosts the secretion of VEGF, which facilitates endothelial cell proliferation, angiogenesis and tumor growth. SOCE-mediated chronic inflammation through activation of Th17 cells is speculated to promote tumor growth. However, in NK, CD8 1 T and Th1 cells, SOCE is required to inhibit tumor progression.
example, the blockade of calcium influx by RO2959, which was developed by Roche, could inhibit proliferation and activation of human T cells as well as cytokine production in these cells. 150 Kim et al. reported that compound 5D prevented the development of experimental autoimmune encephalomyelitis (EAE) in mice, potentially via the inhibition of the differentiation of Th17 cells according to tests in animal models. 120 Until now, no SOCE inhibitors have been approved to treat cancer patients. Carboxyamidotriazole (CAI), a novel synthetic compound that can inhibit stimulated calcium uptake, was reported to exert potent antitumor effects, 151, 152 and has recently been investigated in preclinical studies and clinical trials. Several phase I/II/III clinical trials (http://clinicaltrials.gov/) that involve CAI are currently underway. A phase II trial of CAI in patients with relapsed epithelial ovarian cancer showed that CAI could promote disease stabilization in these patients. Given its limited toxicity profile, it may serve as a maintenance therapy for this disease. 153 
Conclusions and Perspectives
SOCE, an essential component involved in maintaining intracellular Ca 21 homeostasis, regulates several aspects of the malignant behavior of cancer cells, including tumor growth, angiogenesis and metastasis. SOCE represents a promising target for anticancer therapy. The molecular mechanisms and the consequences of aberrant SOCE signaling are contextdependent. As shown in Supporting Information Figure 1 , AKT, ERK, NFAT and COX-2 are critical molecules that act downstream of SOCE. Because the molecular compositions of SOCE and their interactions are complicated, our understanding of the role of SOCE in cancer cells is still limited. STIM/ORAI-mediated SOCE appears to play a dual function during tumorigenesis. On one hand, augmented SOCE has been reported to promote tumor growth and metastasis in a number of cancer types. On the other hand, STIM1 causes growth arrest in the human rhabdomyosarcoma and rhabdoid tumor cell lines RD and G401. 70 In addition, ORAI1 has been reported to facilitate apoptosis of PCa cells, and the knockdown of ORAI1 leads to drug resistance. 71 Thus, the function of SOCE in tumors is inconsistent in different cell types and tumor stages. A careful analysis is necessary to determine the effects of SOCE on tumors.
More attention should be paid to the role of SOCE in immunosuppression. As discussed above, SOCE participates in cytotoxic T-cell differentiation and activation, and during the process of tumorigenesis, the host immune system plays an important role in immune surveillance. In the early stages of tumorigenesis, a small number of premalignant epithelial cells act independently of oncogenic pathways and angiogenesis. Hence, SOCE inhibitors may not exert anticancer effects, but rather, they may promote tumorigenesis because of their immunosuppressive function. After tumor formation, tumor cells acquire immune tolerance, and immune cells in the tumor tissue secrete large amounts of inflammatory cytokines that in turn promote the proliferation of tumor cells and angiogenesis. Based on the aforementioned discussion, there might be specific thresholds of SOCE signaling, so as a therapeutic window might exist, in which functions of cancer cells and proinflammatory Th17 cells can be targeted with moderate SOCE inhibition without affecting antineoplastic functions of NK, CTL and Th1 cells. The blockage of SOCE could suppress tumor growth through the following three mechanisms: (i) the inhibition of proliferation and metastasis of cancer cells; (ii) the inhibition of the activation of immune cells that secrete tumor-promoting inflammatory cytokines and (iii) the inhibition of vascular endothelial cell proliferation, migration, tube formation and angiogenesis.
Because the STIM and ORAI proteins are ubiquitously expressed, toxicity to normal cells should also be considered when SOCE inhibitors are applied systemically. An ideal solution is to develop a class of chemical modulators of CRAC channels that specifically targets tumor cells or tumor vascular endothelial cells. Alternatively, local drug administration could achieve enhanced antitumor effects while reducing toxicity. Furthermore, some known downstream signaling pathways that are regulated by SOCE such as AKT, ERK, COX-2 and NFAT are specifically overexpressed or activated in tumor tissues. These pathways can also be considered for cancer intervention. Since the discovery of the STIM and ORAI proteins, we have witnessed tremendous progress in the mechanistic dissection of SOCE and functional characterization of SOCE deficiency in murine models. Because SOCE plays paradoxical roles in tumorigenesis and tumor progression, the specific role of SOCE in different stages of and types of cancer warrants further investigation.
